---
layout: default
title: Insulin Glargine
parent: 僅模型預測 (L5)
nav_order: 354
evidence_level: L5
indication_count: 10
---

# Insulin Glargine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Insulin Glargine: From Diabetes Mellitus to Autoimmune Oophoritis

## One-Sentence Summary

Insulin glargine is a long-acting basal insulin analogue used as insulin replacement therapy for Type 1 and Type 2 diabetes mellitus.
The TxGNN model predicts it may be effective for **Autoimmune Oophoritis**, with a prediction score of 99.88%,
however there are currently **0 clinical trials** and **0 publications** directly supporting this indication.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Diabetes mellitus (Type 1 and Type 2) — insulin replacement therapy |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Insulin glargine is a recombinant human insulin analogue engineered for prolonged absorption at the subcutaneous injection site, delivering steady basal insulin coverage over approximately 24 hours with no pronounced peak. It acts through the insulin receptor to promote peripheral glucose uptake in muscle and adipose tissue, and to suppress hepatic glucose output, thereby achieving glycaemic control in people with diabetes.

Autoimmune oophoritis frequently co-occurs with Autoimmune Polyglandular Syndrome (APS Type I and Type II). APS encompasses multiple co-existing autoimmune endocrinopathies, and Type 1 diabetes mellitus (T1DM) is a recognised component of both APS I and APS II. Patients who develop APS with T1DM consequently require insulin replacement therapy as standard care, and insulin glargine would be an appropriate basal insulin choice in that context.

The TxGNN model's high prediction score almost certainly reflects this co-morbidity pathway within the underlying knowledge graph — specifically the association chain: **autoimmune oophoritis → APS → T1DM → insulin glargine**. This is an indirect co-morbidity link, not evidence that insulin glargine directly modulates the ovarian autoimmune process. No mechanistic basis currently supports insulin as a therapeutic agent for autoimmune oophoritis itself, and no clinical trials or published literature exist to substantiate this repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Australia Market Information

Insulin glargine has no registered entries in the Australian Register of Therapeutic Goods (ARTG) according to this Evidence Pack. We recommend verifying directly against the TGA ARTG database, as long-acting insulin analogues are in clinical use in Australia and may be listed under specific brand or sponsor entries not captured in this data pull.

---

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN prediction score (99.88%), the association between insulin glargine and autoimmune oophoritis reflects an indirect co-morbidity pathway in the knowledge graph (autoimmune oophoritis → APS → T1DM → insulin use) rather than any direct pharmacological action on the ovarian autoimmune process. With zero supporting clinical trials or literature, this prediction carries no actionable clinical evidence.

**To proceed, the following is needed:**
- Preclinical hypothesis-generating data (in vitro or animal model) demonstrating a direct effect of insulin or insulin signalling on autoimmune oophoritis pathophysiology
- Mechanistic data (MOA) from DrugBank to confirm or refute a plausible immunomodulatory pathway beyond glucose metabolism
- A literature review of whether any insulin class agents have been studied in APS-associated gonadal autoimmunity beyond standard diabetes management
- Verification of Australian ARTG registration status directly against the TGA database
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

